Scott Collins

Read our latest article on Creating an Ownership Culture. This piece dives into how fostering a sense of ownership among employees can lead to remarkable outcomes for both the team and the organization. Here at KKR we are committed to providing ownership to all employees in all new controlled deals, building on recent successes of our Broad-Based Ownership Program. Whether you're a leader seeking to enhance your company's culture or an employee interested in the dynamics of workplace engagement, this article offers valuable perspectives. 👉 Read article here: https://lnkd.in/ejVc2ffd You can download the full report here: https://lnkd.in/ee_vT2rs #Leadership #BusinessCulture #EmployeeEngagement #KKR

28

1 Comment

Many VC fund managers are considering placement agents (PAs) to help secure commitments for the first time. Selecting the right PA and setting up a productive working relationship requires careful consideration. In my latest blog post, I explore essential tips for evaluating and working with PAs, including what to look for in their network, how to structure contracts, and best practices for effective collaboration. If you're navigating the use of placement agents, this guide offers practical insights to increase your fundraising success and avoid common pitfalls- full write up linked below. https://lnkd.in/ey-UcnSG Questions? DM me! #VentureCapital #Fundraising #PlacementAgents #InvestorRelations

25

I recently had the pleasure of speaking with and learning from several software execs from our portfolio companies and industry experts during Thoma Bravo's AI Summit in Miami. It was great to share our insights into trends and practices we see in our portfolio and how we manage opportunities and risks. At TB, we have a long history of guiding enterprise software companies through digital transformation, and we’re already navigating the transition driven by generative AI. Our focus is on managing this new innovation by absorbing the technology to bring meaningful benefits to our portfolio companies and indirectly to their customers. And it’s evolving fast! We see our portfolio companies today using gen AI in generally three ways: first, to create new products and provide customers with incremental use cases. Second, to defend against cyber attacks that have become much more sophisticated by bad actors. And third, as an enabler of talent to make business operations run more efficient and productive. In our view, AI presents a significant growth opportunity, but we also believe that to really maximize that potential, companies should carefully evaluate the risks and be thoughtful about governance, trust, security and data privacy. AI is poised to accelerate innovation and it’s hard to predict the full, transformative potential of AI, but we are confident that some of the advantages of incumbent knowledge and data will be key to unlocking its value.

209

3 Comments

Series A or B wondering when to bring in a VP of Finance or CFO? It’s a crucial decision that can shape the future of your company. At this stage, financial leadership is not just about managing numbers but also scaling processes, securing funding, and driving strategic growth. My colleague Paul breaks down key signs that it’s time to hire and indicators for choosing between VP of Finance and a CFO #FinanceLeadership #CFO #StartupGrowth #SeriesA #SeriesB #NextGenLeadership

7

Our partner Eddie Eltoukhy has identified these opportunities in Biotech. Eddie has a PhD in bioengineering from Massachusetts Institute of Technology and over a decade experience as an operator. Reach out to him if you are working on these areas of biotech. Pear VC - Technology-Driven Therapeutic Platforms Companies developing therapeutic assets with a core product engine Proprietary tool, workflow, or samples leading to novel biological data sets Preference for omics platforms or high throughput screening / engineering workflows First-in-class or best-in-class drugs - Next-Generation Therapeutic Modalities Technologies to improve the efficacy, safety, access, or reach of next-gen modalities including the following: Genomic medicines (gene tx & gene editing) Cell therapies Targeted protein degraders Antibody-drug conjugates Radiopharma - Precision Medicine New technologies supporting the discovery of novel biomarkers and the generation of proprietary data sets for applications in: Disease screening Therapy selection Recurrence monitoring - Life Sciences + AI Software Platforms Software & AI-driven platforms to improve all aspects of life sciences R&D, including: Target discovery and validation Drug design and optimization Manufacturing Regulatory Clinical development

118

5 Comments

Happy news from one of our Fund I portfolio companies (which willl hopefully make our investors happy, DPI baby!): https://lnkd.in/e5bPu5qx Personal Thoughts: - My great admiration for the Biocatch team, I've witnessed your achievements and ultimate interim payoff - Bold move from Permira, you got yourselves a strong asset - Constantly reading aggregated data from the VC industry, which is good, but also very misleading. Why? Because as in the economy, even in a bear market, the good and healthy companies will ultimately thrive. Don't rely on aggregated data only

33

3 Comments

With everything that Shahzad M. Khan and I have going on at Devonshire Partners, I have not had as much time to source great new guests for the Compounders podcast. So I figured, why not use my wonderful network of LinkedIn contacts and followers to find some new people to have on the show? As many of you know, we essentially do three types of interviews: with investment professionals, private company CEOs, and public company CEOs. I am going to lay out some basic criteria, with examples, for each category but am open even if people don't fit exactly within these boxes: Investment professionals: -Any equity or fixed income manager running more than $25mm. (See my great interviews with Scott B Colson, CFA, CAIA and Greg Dean, CFA.) -Investors who recently launched their own firm after a long career working for other firms. (For example, my recent interview with James Edwards, CFA, CPA) -Equity investors who focus on microcap (Like my interviews with Mathieu Martin, CFA and Whit Huguley, CFA) -Lower middle market and middle market PE firms (See my interview with Brandon Halcott) -We have never had a VC investor on and I would love to have one on (Yes, Alex Rubalcava I am talking to you) -Anyone who runs a fund or firm focused on real estate development or acquisitions (Don't miss my interview with Evan Curtis) -People running strategies involving esoteric asset classes (Even though he invests in equities, I consider Thomas Bachrach someone who makes very esoteric investments). Public company CEOs: -Any CEO of a profitable, non-commodity-based company that has a market cap above $50mm. (A good example was my recent interview with Carl H. of Corero Network Security) Private Company CEOs: -I am pretty open here. I just like talking to people who are building a business they think they compound, with a preference for a company that is doing something differentiated. (Maybe the best example of this is my conversation with Thomas Li of Daloopa) In reality, I have a lot of fun doing the interviews so please feel free to reach out if you want to be on the show or if someone you know could be a good fit. You can message me on LinkedIn or at [email protected]. You can find all of the 75+ episodes we have done here: https://lnkd.in/gr26rPan Thanks so much for the help!

30

2 Comments

Hark's Founder and Managing Partner Doug Cruikshank will join in on the following panel on September 12 at the NYC Private Debt Conference. As the lines continue to blur between NAV Solutions and Secondaries, it is important for GPs and LPs to continue their education on these key topics.  #Secondaries #FundFinance #NAVSolutions #NAVFinancing #PrivateEquity #PrivateDebt #PrivateCredit

26

The biotech sector is evolving rapidly, making resilience more critical than ever. I’m pleased to share our team's report, which highlights this dynamic shift. It’s inspiring to see how the biotech industry leverages its intrinsic innovative mindset to explore new avenues for fundraising, IPOs, and collaborations. Cindy (Xin) XiongLuna Ji Paul Lu Donnie McGrathBruce BoothRicky SunSrini AkkarajuJeffrey TongAnna FanNandita ShangariLianshan ZhangMichael Yu Our latest report, "Thriving Amid Capital Winter: How Biotech Companies Leverage Creative Strategies for Growth & Successful Exits," highlights innovative strategies from leading companies, including Gracell Biotechnologies & AstraZeneca, Novartis & SanReno Therapeutics, @Gyre Therapeutics & @Catalyst Biosciences, Bayside Lakeshore Bio & Apollomics, Shanghai Allist Pharmaceuticals Co., Ltd & ArriVent Biopharma, Hengrui Pharma Co.,Ltd & Hercules, @KeyMed Bio & Belenos, Genor & TRC 20024, EpimAb Biotherapeutics, Inc. & Vignette Bio, Bayer, RTW Investments, LP & CORXEL Pharmaceuticals, Sanofi & Innovent Biologics, and CBC Group & Paratek Pharmaceuticals, Forsite Capital, RTW Investments, LP From M&A strategies and the NewCo model to royalty-based financing and strategic collaborations, learn how these companies are navigating market challenges, driving innovation, and securing growth opportunities. 💡 Discover actionable insights to position your biotech business for success in today’s capital-constrained environment. Access full Report: 🔗 https://lnkd.in/dEdb3Pwd Let’s navigate this capital winter together and build a stronger, more sustainable biotech future. hashtag #biotech hashtag #capitalmarkets hashtag #growthstrategies hashtag #innovation hashtag #MSQVentures hashtag #NewReport hashtag #biotechindustry

11

The case for emerging managers: “What we don’t want to do is lock ourselves out of these high-performing, differentiated strategies for the simplicity of going with the big guys”, Taffi Ayodele director of the emerging manager strategy at the NYC Office of the Comptroller #investmentstrategies #investmentreturns #roi #assetallocation #emergingmanagers #riskreward #premium #performance

4

To all #founders and #entrepreneurs out there, our intro meetings are conversational and easy going. Feel free to message me to setup a call. Learn what Pioneera Ventures can do for you!

22

Abby Levy talks about venture's role in US healthcare and what we can expect to see as technology impacts the space on TFR. Check out the rest of the conversation with Abby & Alan Patricof of Primetime Partners on Episode 433.

35

6 Comments

Interesting piece from Marc Andreessen on how startups are not getting the regulatory support they need to sustain America's technological leadership. "Regulatory agencies have been green lit to use brute force investigations, prosecutions, intimidation, and threats to hobble new industries, such as Blockchain. Regulatory agencies are being green lit in real time to do the same to Artificial Intelligence." While many investors themselves (both in the US and Europe) are worried how AI will change our lives, our jobs and social interactions, the top VC opinion leader thinks regulation is already too restrictive. #techstartups #techleadership #strategicgrowth

9

1 Comment

Great time on the Embracing Erosion podcast w/Devon O'Rourke! We talked about: 🚀 How to scale a company from concept to 9-figure exit 🔄 How to break away from the traditional consulting model and apply product approaches ⏩ Why it’s important to iterate quickly and often with messaging 💸📈What signals are important to pay attention to when investing in startups and much more!

1

1 Comment

Excellent 45 second explanation of why organizations with the best intelligence, in today's Global Competition environment - win.

20

1 Comment

Good article on drivers of VC secondary market with great insights from my partner Ravi.

17

TL;DR - 1) Mario & team at Oscar are testing (and writing about) LLMs in real-world healthcare applications and their blog is a good read for the AI-curious. 2) o1, even in preview format, is a must-try to address complex problems where 4o might not have delivered consistent results. Hopefully folks are starting to set up AI-sandboxes with test data and tinkering!

49

1 Comment